Mometasone
Active ingredient · 4 therapeutic classes
Sold as OVIXAN
- Drug class
- Glucocorticoids
- Availability
- Prescription only
- Routes
- Topical, Nasal
- Markets covered
- 3
- Products on record
- 55
Overview
Mometasone is an active pharmaceutical ingredient in the Glucocorticoids group (R03BA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 50 | May 22, 2026 |
| US United States | FDA | 3 | May 8, 2026 |
| CA Canada | Health Canada | 2 | June 13, 2025 |
GBUnited Kingdom· MHRA
50 products
Uses
1% w/w Ointment is indicated for the symptomatic treatment of inflammatory and pruritic skin conditions which respond to external treatment with glucocorticoids, such as atopic dermatitis and psoriasis (excluding widespread plaque psoriasis).
1% w/w Ointment should be preferably used to treat very dry, scaly and cracked skin complaints where a topical mometasone preparation is indicated.
How to take
USUnited States· FDA
3 products
Uses
1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 2 years of age or older. 1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients ≥ 2 years of age.
( 1 )
How to take
CACanada· Health Canada
2 products
How to take
2 PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS ...................................................................................................................
3 CONTRAINDICATIONS .................................................................................................. 3 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ...................................................................................................
6 DRUG INTERACTIONS ................................................................................................... 8 DOSAGE AND ADMINISTRATION ............................................................................... 9 OVERDOSAGE ...............................................................................................................
Sources & citations
- [1]MHRA (UK) · PL045690886 · revised April 10, 2026
- [2]FDA DailyMed · 031283ed-988b-46… · revised July 9, 2019 [PDF]
- [3]Health Canada (DPD) · 02519127 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.